AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Net Income
Bottom-line profit, the starting point for calculating cash from operations.
AC Immune S.A.NASDAQ: ACIU
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income dips below year-ago levels
Q4 FY2025 net income of CHF 14.26M (cash outflow) fell 9.7% year over year, behind the +38.1% change in trailing-twelve-month net income. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.
Context
- Net income amounted to 1883.0% of revenue in FY2025, up 1696.6 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -CHF 40.1M (-40.4%) for the fiscal year ending Dec 2026, a slowdown from the +32.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -CHF 14.26M-10.1% QoQ
- Last fiscal yearDec 2025
- -CHF 67.28M+32.1% YoY
- LTMDec 2025
- -CHF 70.34M+38.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.7% | -20.6% | -10.9 pp |
| 1 year | +32.1% | -40.4% | -72.5 pp |
| 3-year CAGR | -1.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CHF · from the cash flow
- Latest · FY2025
- (67.28M) CHF
- Year-over-year change
- -32.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.28M) | -32.1% |
| FY2024 | 2024-12-31 | (50.92M) | +6.1% |
| FY2023 | 2023-12-31 | (54.23M) | +23.3% |
| FY2022 | 2022-12-31 | (70.75M) | +3.1% |
| FY2021 | 2021-12-31 | (73M) | — |
Net Income vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +38.1% is the 2nd highest of 10, against a peer median of +17.3%.
- Net income amounts to 1968.6% of revenue for ACIU, versus a peer median of 7142.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $246.41M USD | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $196.48M USD | +17.4% | +13.3% | — | |
| LTM Mar 2026 | $145.44M USD | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $74.31M USD | +17.6% | +31.7% | — | |
| LTM Dec 2025 | CHF 70.34M CHF | +38.1% | -1.7% | 1968.6% | |
| LTM Mar 2026 | $67.27M USD | +11.1% | -11.8% | 98.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $58.44M USD | +17.3% | +35.2% | — |
| LTM Dec 2025 | $42.63M USD | +34.3% | +8.1% | — | |
| LTM Mar 2026 | $35.71M USD | -24.3% | -0.3% | 7142.0% | |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| LTM Mar 2026 | $5.23M USD | +106.0% | -28.4% | 2.4% | |
| Peer median (excluding ACIU) | — | +17.3% | +10.7% | 7142.0% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (67.28M) |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.39M |
| Deferred Income Tax | 130K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.13M | 3.33M | 4.37M | 5.47M | 0 |
| Change in Working Capital | 6.84M | (8.43M) | (15.16M) | 107.51M | (6.47M) |
| Accounts Receivables | (99K) | 603K | (14.8M) | 13.55M | 877.68K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (565.39K) |
| Other Working Capital | 6.94M | (9.04M) | (360K) | 93.96M | (6.78M) |
| Other Non-Cash Items | (6.2M) | (72K) | 2.41M | 1.61M | 5.21M |
| Operating Cash Flow | (65.69M) | (73.57M) | (60.41M) | 65.84M | (66.15M) |
| Capital Expenditures | (2.64M) | (1.24M) | (801K) | (576K) | (859.54K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 14.33K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 61.69M |
| Other Investing Activities | (51.03M) | 25M | 66.45M | (104.71M) | (162.36K) |
| Investing Cash Flow | (53.66M) | 23.76M | 65.65M | (105.29M) | 60.69M |
| Debt Repayment | 22.95M | (569K) | (548K) | (683K) | (1.03M) |
| Common Stock Issued | 17.8M | 7K | 43.8M | 111K | 5.73K |
| Common Stock Repurchased | 0 | (8K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6K) | (776K) | 0 | (548K) | 46.13K |
| Financing Cash Flow | 40.75M | (1.35M) | 43.25M | (1.12M) | (974.14K) |
| Effect of Forex Changes | (70K) | 521K | (1.58M) | (1.65M) | 1.51M |
| Net Change in Cash | (78.68M) | (50.63M) | 46.91M | (42.22M) | (4.92M) |
| Free Cash Flow | (68.32M) | (74.81M) | (61.21M) | 65.27M | (67.01M) |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.